**Core Concept:**
Heparin-induced thrombocytopenia (HIT) is a type of drug-induced immune-mediated thrombocytopenia (decrease in platelet count) and a hypercoagulable state. Heparin is a commonly used anticoagulant to prevent and treat blood clots. The immune system recognizes the heparin-platelet complex as foreign, leading to the production of antibodies. These antibodies bind to and activate platelets, causing the destruction of platelets and activation of coagulation cascade, resulting in thrombocytopenia and increased risk of thrombosis (blood clots).

**Why the Correct Answer is Right:**
The correct answer is **D:**

D. Ticlopidine

Ticlopidine is a thienopyridine class of antiplatelet drug which works by blocking the P2Y12 receptor on platelet, preventing the binding of adenosine diphosphate (ADP) and adenosine triphosphate (ATP) to the receptor. This blocks platelet activation and aggregation, thereby reducing the risk of thrombosis. However, it does not have the risk of triggering HIT as it is not used as an anticoagulant and does not share a similar structure to heparin.

**Why Each Wrong Option is Incorrect:**

A. Enoxaparin: Enoxaparin is a low molecular weight heparin (LMWH) which is a derivative of unfractionated heparin (UFH). Heparin is known to cause HIT, and enoxaparin shares its structure, making it a wrong choice.

B. Warfarin: Warfarin is a vitamin K antagonist that inhibits vitamin K-dependent clotting factors, preventing the formation of blood clots. Warfarin does not cause HIT as it doesn't share a similar structure to heparin.

C. Aspirin: Aspirin is an irreversible inhibitor of platelet cyclooxygenase enzymes COX-1 and COX-2, blocking the synthesis of prostaglandins and thromboxanes which are essential for platelet aggregation. However, aspirin does not cause HIT as it does not share a similar structure to heparin.

**Clinical Pearl:**
Clinicians should be aware of the potential for heparin-induced thrombocytopenia in patients receiving heparin therapy and consider alternative anti-coagulation agents like enoxaparin, fondaparinux, or direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, or edoxaban.

**Why to Choose Ticlopidine over Enoxaparin:**
Ticlopidine and enoxaparin both are anticoagulants, but the structural similarity to heparin makes enoxaparin a wrong choice for preventing HIT. Ticlopidine is a P2Y12 inhibitor, inhibiting adenosine diphosphate (ADP) receptors on platelets, preventing platelet activation and aggregation. Although ticlopidine has some risk of inducing HIT, it is less likely to cause HIT than enoxaparin due to its different structure.